DTDennis F. Thompson

Dennis F. Thompson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dennis F. Thompson has a total of 151 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Publication records and bibliometric indices of postprofessional pharmacy fellowship directors

    by Dennis F. Thompson, Stephen D. Drinnon

    Background: Scholarship is an essential component of fellowship programs. Postprofessional fellowship directors are considered research mentors, but their publication records have not been documented.Objectives: The primary purpose of this research was to characterize the publication records and bibliometric indices of the current postprofessional fellowship directors listed on the American College of Clinical Pharmacy (ACCP) website. A secondary purpose was to compare the publication metrics of distinct groups within this cohort.Methods: Using the Web of Science database, the publication records of all listed postprofessional fellowship directors on the ACCP website were collected. Forty‐nine unique directors were identified from the website. Bibliometric indices calculated included: lifetime publications, publications/year, h‐index, m‐quotient, lifetime citations, citations/year, average citations/paper, productivity, and creativity. In addition, we compared peer reviewed fellowship directors and non‐peer‐reviewed fellowship directors, infectious disease fellowship directors, and noninfectious disease fellowship directors, and National Institutes of Health (NIH)‐funded fellowship directors and non‐NIH funded directors. The Kruskal‐Wallis analysis of variance for nonparametric data was used to assess differences between groups. The a priori level of significance was set atP < .01.Results: Within our research cohort, 12 (24%) of the fellowship directors had less than 10 lifetime publications and 12 (24%) had an h‐index of less than five. Infectious disease directors had higher bibliometric indices than noninfectious disease directors (P < .01) as did NIH‐funded researchers when compared with their nonfunded counterparts (P < .01). Gender differences, secondary degrees, and peer‐review status were not significantly different between groups.Conclusion: Fellowship directors should possess an established record of scholarly activity to function in the role of research mentor. Benchmarking of bibliometric indices could be an important tool in the overall evaluation of fellowship director qualifications in the future.

  • Open Access

    Publication Records and Bibliometric Indices of Pharmacy School Deans

    by Dennis F. Thompson

    Objective. To characterize the publication records and bibliometric indices of current CEO deans at pharmacy schools and colleges in the United States. Methods. Using the Web of Science database, the publication records of all CEO pharmacy deans in the US were collected. Bibliometric indices calculated included: lifetime publications, publications/year, h-index, m-quotient, lifetime citations, citations/year, average citations/paper, productivity, and creativity. The Kruskal-Wallis analysis of variance for nonparametric data was used to assess differences between groups. Results. All bibliometric parameters were different between pharmacy schools and colleges that were research-intensive vs teaching-intensive, academic health center-based vs non-academic health center-based, and public vs private. Additionally, the discipline and degree of each dean yielded significant differences. There were no significant differences in bibliometric parameters between male or female deans. Conclusion. Deans of current SCOP display a varied range of publication records and bibliometric indices.


  • A Review and Assessment of Drug-Induced Thrombocytosis

    by Quyen T. Vo, Dennis F. Thompson

    Objectives: The purpose of this article is to review the current literature on drug-induced thrombocytosis with the goal of critically assessing causality and providing a comprehensive review of the topic. Thrombopoietic growth factors, such as thrombopoietin-receptor agonists (romiplostim and eltrombopag) and erythropoietin are not included in our review. Data Sources: The literature search included published articles limited to the English language and humans in MEDLINE, EMBASE, and Web of Science databases. MEDLINE/PubMed (1966 to September 2018) was searched using the MeSH terms thrombocytosis/chemically-induced and thrombocytosis/etiology . EMBASE (1980 to September 2018) was searched using the EMTAGS thrombocytosis/side effect . Web of Science (1970 to September 2018) was searched using the search term thrombocytosis . References of all relevant articles were reviewed for additional citations and information. Study Selection and Data Extraction: Review articles, clinical trials, background data, case series, and case reports of drug-induced thrombocytosis were collected, and case reports were assessed for causality using a modified Naranjo nomogram. Data Synthesis: Drug-induced thrombocytosis, a form of reactive thrombocytosis cannot be easily differentiated from more common etiologies of reactive thrombocytosis. In all, 43 case reports of drug-induced thrombocytosis from a wide variety of drugs and drug classes were reviewed using a modified Naranjo probability scale that included criteria specific for thrombocytosis. Conclusions: Drug-induced thrombocytosis is a relatively rare adverse drug reaction. The strongest evidence of causality supports low-molecular-weight heparins and neonatal drug withdrawal. Weaker evidence exists for all-trans retinoic acid, antibiotics, clozapine, epinephrine, gemcitabine, and vinca alkaloids.


  • The political ethics of political campaigns

    by Dennis F. Thompson

    What principles should we use to judge the conduct of political campaigns? The principles should focus on the ability of voters to exercise free choice. Campaigns are not, and arguably should not be, moments of civic deliberation. But neither should they be occasions for misinformation and manipulation. This chapter examines examples of campaign practices that manifest these vices, and develops criteria grounded in democratic theory to criticise them. The criteria also point to changes in the policies that govern campaigns and the institutions that support them.


  • Clinical Toxicology of Yew Poisoning

    by Alexander W. Labossiere, Dennis F. Thompson

    Objectives: Yew plant materials contain highly toxic taxine alkaloids. Serious ingestions can result in life-threatening toxicity. The purpose of this article is to summarize the literature on the treatment of acute yew poisoning. Data Sources: PubMed (January 1946 to November 2017) was searched using the search terms “taxus/po”. EMBASE (1980 to November 2017) was searched using the search terms “taxus/to” and “yew.mp.” Web of Science (1945 to November 2017) was searched using the text words taxus, taxine, and yew. Study Selection and Data Extraction: Available English language articles involving case reports, epidemiology, treatment, and outcomes were included. Data Synthesis: Although not uncommon, unintentional yew poisoning rarely results in significant morbidity or mortality. A total of 26 case reports of yew poisoning were evaluated along with 4 case series articles (totaling 22 additional cases). Only 4 of the 48 total cases (8%) were accidental poisonings, the rest being deliberate ingestions. In 20 patients (42%), it resulted in fatalities. Severe, acute yew poisoning results in symptomatology largely resistant to pharmacotherapy intervention. Conclusions: Most nonintentional ingestions of yew plant constituents are asymptomatic and require little intervention. Severe poisoning can result in life-threatening cardiac toxicity and require aggressive supportive care. Therapeutic interventions, such as sodium bicarbonate, digoxin immune fab, and hemodialysis that have been utilized in case studies and case series in the literature have little proven benefit. Extracorporeal life support should be considered in severe yew poisoning.


  • Prophylaxis of migraine headaches with riboflavin: A systematic review

    by D. F. Thompson, H. S. Saluja

    Migraine headache is a relatively common, debilitating condition that costs our healthcare system over 78 billion dollars per year. Riboflavin has been advocated as a safe, effective prophylactic therapy for the prevention of migraines. The purpose of this study was to provide a systematic review of the current role of riboflavin in the prophylaxis of migraine headache. A MEDLINE literature search inclusive of the dates 1966-2016 was performed using the search terms: riboflavin and migraine disorders. Excerpta Medica was searched from 1980 to 2016 using the search terms: riboflavin and migraine. Additionally, Web of Science was searched using the terms riboflavin and migraine inclusive of 1945-2016. Bibliographies of all relevant papers were reviewed for additional citations. We utilized the PRISMA guidelines to select English language, human, clinical trials of riboflavin as a single entity or in combination, review articles, and supporting pharmacokinetic and pharmacogenomic data assessing the efficacy and mechanism of riboflavin therapy in the prophylactic treatment of migraine headache. A total of 11 clinical trials reveal a mixed effect of riboflavin in the prophylaxis of migraine headache. Five clinical trials show a consistent positive therapeutic effect in adults; four clinical trials show a mixed effect in paediatric and adolescent patients, and two clinical trials of combination therapy have not shown benefit. Adverse reactions with riboflavin have generally been mild. Riboflavin is well tolerated, inexpensive and has demonstrated efficacy in the reduction of adult patient's migraine headache frequency. Additional data are needed, however, to resolve questions involving pharmacokinetic issues and pharmacogenomic implications of therapy.


  • Antibiotic-Induced Rash in Patients With Infectious Mononucleosis

    by Dennis F. Thompson, Carroll L. Ramos

    Objective: To provide an extensive review of case reports, epidemiological data, and the underlying mechanism of antibiotic-induced skin rash in patients with concurrent infectious mononucleosis (IM). Data Sources: A MEDLINE literature search inclusive of the dates 1946 to June 2016 was performed using the search terms anti-bacterial agents and infectious mononucleosis . EMBASE (1980 to June 2016) was searched using the terms mononucleosis and antibiotic agent and drug eruption . References of all relevant articles were reviewed for additional citations and information. Study Selection and Data Extraction: We selected English-language, primary literature, review articles, and mechanistic articles that addressed antibiotic-induced skin rash in patients with concurrent IM. We assessed all case reports available for causality utilizing a modified Naranjo nomogram specifically designed for this subject. We assembled the available epidemiological data into tables to identify trends in incidence rates over the years. Data Synthesis: We identified 17 case reports of antibiotic-associated rash in patients with IM. The median Naranjo score was 6 (range = 1 to 8). The top 3 reported drugs were ampicillin, azithromycin, and amoxicillin. Incidence of this adverse effect was higher in the 1960s (55.6%, 45%, and 33%) than in 2013 (33% and 15%). The mechanism most commonly proposed is a transient virus-mediated immune alteration that sets the stage for loss of antigenic tolerance and the development of a reversible, delayed-type hypersensitivity reaction to the antibiotic. Conclusion: A reassessment of the long-held belief of the high incidence (80%-100%) of antibiotic-induced skin rash in patients with IM seems prudent. Additional studies will be necessary to clarify this issue.


  • Nebulized Fentanyl in Acute Pain

    by Joshua P. Thompson, Dennis F. Thompson

    Objective: To provide a systematic review of the current role of nebulized fentanyl in acute pain and potentially other conditions. Data Sources: A MEDLINE literature search inclusive of the dates 1946 to May 2016 was performed using the following search terms: fentanyl and administration, inhaled. Excerpta Medica was searched from 1980 to May 2016 using the following search terms: exp fentanyl/inhalation drug administration. Additionally, Web of Science was searched using the terms fentanyl and pain inclusive of 1945 to May 2016. Study Selection and Data Extraction: We utilized the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines to select English language, human primary literature, review articles, and supporting data assessing the efficacy of nebulized fentanyl in acute pain. Data Synthesis: Seven clinical trials have demonstrated no difference in efficacy between nebulized fentanyl and intravenous (IV) opioids. Few adverse effects were reported; however, the trials were of short duration. Nebulized fentanyl appeared to be a rapid-acting analgesic that does not require IV access. Conclusion: Evidence suggests that nebulized fentanyl is as effective as IV opioids in the treatment of acute pain, with relatively few adverse effects. However, questions remain about the extemporaneous preparation of fentanyl nebulized solution, the variability in nebulization devices, and ensuring consistent drug delivery to distal airways in the clinical setting. The abuse potential of nebulized fentanyl should also be considered.


  • Role of Clonidine in Neonatal Abstinence Syndrome

    by Vonya N. Streetz, Brooke L. Gildon, Dennis F. Thompson

    Objective: To provide a systematic review of the current role of clonidine in neonatal abstinence syndrome (NAS). Data Sources: A MEDLINE literature search inclusive of the dates 1946 to November 2015 was performed using the search terms clonidine and abstinence syndromes, neonatal. Excerpta Medica was searched from 1980 to November 2015 using the search terms clonidine and newborn. Additionally, Web of Science was searched using the terms clonidine and neon* inclusive of 1945 to November 2015. Study Selection and Data Extraction: We utilized the PRISMA guidelines to select English language, human primary literature, review articles, and supporting data assessing the efficacy of clonidine in the treatment of NAS. Data Synthesis: Three clinical trials and 5 observational studies demonstrated evidence of clonidine’s effectiveness in NAS. Clonidine’s therapeutic use as monotherapy and in combination with other agents was shown to reduce the time needed for pharmacotherapy treatment. Adverse reactions associated with clonidine in neonates, when reported, are mild. Conclusion: The American Academy of Pediatrics recommends opioids as first-line agents in the treatment of NAS when pharmacological treatment is indicated. Limited data suggest that clonidine, in combination with other agents or as monotherapy, may be as effective, with minimal adverse effects and reduced treatment time. Prospective clinical trials are necessary to clarify the ultimate role of clonidine in NAS and establish long-term safety.